Universal DX develops next-generation diagnostics that combine AI, machine learning and molecular analysis with liquid biopsy to identify DNA patterns for early cancer detection. The company claims significantly higher sensitivity for detecting early-stage colorectal cancer and precancerous lesions versus traditional methods. Universal DX primarily serves laboratories and diagnostic operators in the US. It is finalising commercial approval for its colorectal cancer detection test and is developing comparable tests for lung, liver, pancreatic and oesophageal cancers. The recent financing round totals €62 million, with SETT contributing €29.9 million from its Next Tech facility backed by EU Next Generation funds. The funding is directed at advancing its AI-powered tests toward commercialisation and expanding its pipeline of cancer diagnostics.

Total raised

$128M

Funding rounds

3

Latest round

Equity

Latest activity

May 2026